Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients
Introduction. Psoriasis is a relatively common chronic inflammatory disease. It clinically manifests as raised, well defined erythematous plaques with irregular borders and silvery scales. Psoriasis appears to be mediated by abnormal immune system functioning, including T lymphocyte and macrophage a...
Main Authors: | Beltammer Belkais, Gargoom Ali, Taeib Ghada, Duweb Gamal |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2019-03-01
|
Series: | Serbian Journal of Dermatology and Venereology |
Subjects: | |
Online Access: | https://doi.org/10.2478/sjdv-2019-0002 |
Similar Items
-
Ustekinumab treats psoriasis by suppressing RORC and T-box but its suppression of GATA restrains its efficacy
by: Lun-Fei Liu, et al.
Published: (2019-04-01) -
Ustekinumab Drug Survival in Patients with Psoriasis: A retrospective Study of Real Clinical Practice
by: Cristina Galache Osuna, et al.
Published: (2020-10-01) -
Ustekinumab successfully treated a patient with severe psoriasis vulgaris with primary failure to infliximab and secondary failure to adalimumab
by: Chiharu Tateishi,, et al.
Published: (2015-07-01) -
Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience
by: Ting-Shun Wang, et al.
Published: (2017-03-01) -
Use of ustekinumab after other biological therapies in moderate-severe psoriasis: Real long-term data
by: Manuel David Gil-Sierra, et al.
Published: (2020-09-01)